The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 710-717

  Zhang, Xudong ^a   Zhao, Lu ^b   Chen, Changying ^c   Yan, Jiaqin ^a   Zhou, Chaofeng ^a   Yue, Guangxing ^a   Tian, Li ^a   Zhang, Mingzhi ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Department of Neurology ^*  (China)

^c Outpatient Department   (China)

Author keywords

Bcl 2; Lentivirus; Lymphoma; ShRNA; TRAIL

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; COMPLEMENTARY DNA; DEATH RECEPTOR 4; PROTEIN BCL 2; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LENTIVIRINAE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BLOTTING, WESTERN; BYSTANDER EFFECT; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; JURKAT CELLS; LENTIVIRUS; LYMPHOMA; MICROSCOPY, FLUORESCENCE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84859081916     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631158     Document Type: Article

References (44)

1. Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol 2000;12:383-394.
2. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51: 983-994.
3. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010;51:376-389.
4. Ahmed S, Winter JN, Gordon LI, et al. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: Current status and future applications. Leuk Lymphoma 2010;51:1163-1177.
5. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non- Hodgkin's lymphoma. J Clin Oncol 2011;29:1876-1884.
6. Buttgereit P, Schakowski F, Marten A, et al. Eff ects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer Gene Ther 2001;8:430-439.
7. Ebert O, Wilbert D, Buttgereit P, et al. Eff ects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC. Genet Vaccines Ther 2004;2:15.
8. Misumi M, Suzuki T, Moriuchi S, et al. In vitro thymidine kinase/ ganciclovir-based suicide gene therapy using replication defective herpes simplex virus-1 against leukemic B-cell malignancies (MCL, HCL, B-CLL). Leuk Res 2003;27:695-699.
9. Buttgereit P, Schmidt-Wolf IG. Gene therapy of lymphoma. J Hematother Stem Cell Res 2002;11:457-467.
10. Godfrey A, Anderson J, Papanastasiou A, et al. Inhibiting primary eff usion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005;105:2510-2518.
11. Buttgereit P, Weineck S, Ropke G, et al. Effi cient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther 2000;7:1145-1155.
12. Zhu J, Chen Y. [Research of lentiviral vector mediated growth factor gene-modifi ed bone marrow mesenchymal stem cells]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010;24:972-976.
13. Zhang X, Zhao L, Hang Z, et al. Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncol Rep 2011;26:637-644.
14. Alain T, Th irukkumaran C, Morris DG, et al. Lymphomas and oncolytic virus therapy. Clin Lymphoma 2003;4:104-111.
15. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
16. Paoluzzi L, O' C onnor OA. Targeting survival pathways in lymphoma. Adv Exp Med Biol 2010;687:79-96.
17. Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010;37:299-310.
18. Welbourne T, Nissim I. Regulation of mitochondrial glutamine/ glutamate metabolism by glutamate transport:studies with (15)N. Am J Physiol Cell Physiol 2001;280:C1151-C1159.
19. Th orburn A. Tumor necrosis factor-related apoptosis-inducing ligand (trail) pathway signaling. J Thorac Oncol 2007;2:461-465.
20. Wajant H. CD95L/FasL and trail in tumour surveillance and cancer therapy. Cancer Treat Res 2006;130:141-165.
21. Johnstone RW, Frew AJ, Smyth MJ. The trail apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-798.
22. Falschlehner C, Schaefer U, Walczak H. Following Trail's path in the immune system. Immunology 2009;127:145-154.
23. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010;29:4752-4765.
24. Begue B, Wajant H, Bambou JC, et al. Implication of TNF-related apoptosis-inducing ligand in infl ammatory intestinal epithelial lesions. Gastroenterology 2006;130:1962-1974.
25. Wiley SR, Schooley K, Smolak PJ, et al. Identifi cation and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
26. Griffith TS, Stokes B, Kucaba TA, et al. trail gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009;9:9-19.
27. Shah K, Tung CH, Yang K, et al. Inducible release of trail fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 2004;64:3236-3242.
28. Kock N, Kasmieh R, Weissleder R, et al. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007;9:435-442.
29. Abdulghani J, El-Deiry WS. trail receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091-1108.
30. Secchiero P, Vaccarezza M, Gonelli A, et al. TNF-related apoptosisinducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 2004;10:3673-3681.
31. Lois C, Hong EJ, Pease S, et al. Germline transmission and tissuespecifi c expression of transgenes delivered by lentiviral vectors. Science 2002;295:868-872.
32. Zhao Y, Zhang CL, Zeng BF, et al. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun 2009;390:642-647.
33. Sastry L, Johnson T, Hobson MJ, et al. Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther 2002;9:1155-1162.
34. Kuhn DM, Balkis M, Chandra J, et al. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003;41:506-508.
35. Seol JY, Park KH, Hwang CI, et al. Adenovirus-TRAIL can overcome trail resistance and induce a bystander eff ect. Cancer Gene Ther 2003;10:540-548.
36. Huang X, Lin T, Gu J, et al. Cell to cell contact required for bystander eff ect of the TNF-related apoptosis-inducing ligand (trail) gene. Int J Oncol 2003;22:1241-1245.
37. Lu G, Punj V, Chaudhary PM. Proteasome inhibitor bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing ' s sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008;7:603-608.
38. Liang XS, Caporaso N, McMaster ML, et al. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 2009;146:418-423.
39. Cheng J, Hylander BL, Baer MR, et al. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006;5:1844-1853.
40. Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-1132.
41. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002;21:2283-2294.
42. Anastasov N, Klier M, Koch I, et al. Effi cient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop 2009;2:9-19.
43. Abbas-Terki T, Blanco-Bose W, Deglon N, et al. Lentiviralmediated RNA interference. Hum Gene Ther 2002;13:2197-2201.
44. Keim C, Grinstein V, Basu U. Recombinant retroviral production and infection of B cells. J Vis Exp 2011;(48). pii: 2371.